Clinical Stroke Research
Stroke research is a vital component for patients at Cedars-Sinai's Stroke Program. Director David Palestrant,MD, and the Stroke Program's staff are currently involved in National Institutes of Health (NIH)-funded clinical trials relating to stroke prevention, acute stroke therapy and neuroimaging in stroke.
Because of their active participation in these and other clinical stroke research trials, Dr. Waters and his staff remain up to the minute in knowledge of new stroke therapies and can discuss the best treatment options for stroke patients.
In turn, their patients benefit by having the latest information on stroke prevention and treatment and, as appropriate, can participate in clinical research.
Current Clinical Trials
The Stroke Program at Cedars-Sinai is currently participating in several clinical trials. The following links are to outside sources that contain information about some of the current therapies that the program is investigating.
Closed Clinical Trials
- Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)
- Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS)
- Insulin Resistance Intervention after Stroke Trial (IRIS) -- currently on hold
Clinical Trials National Directory
Awards and Outcomes
Stroke Achievement Award
Representatives of the American Heart Association recently presented Cedars-Sinai with its "Get with the Guidelines-Stroke Gold Performance Achievement Award." The award recognizes Cedars-Sinai's success in implementing a higher standard of stroke care.
To receive the award, honorees have to demonstrate 85 percent adherence to the "Get with the Guidelines-Stroke" key measures for 24 or more consecutive months. These measures include aggressive use of medications like tPA, anti-thrombotics, anticoagulation therapy, DVT prophylaxis, cholesterol-reducing drugs and smoking cessation.
To learn more about this award, please click here.
